Is Allarity Therapeutics Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 1 Wall Street analyst covering (NASDAQ: ALLR) stock is to Hold ALLR stock.
Out of 1 analyst, 0 (0%) are recommending ALLR as a Strong Buy, 0 (0%) are recommending ALLR as a Buy, 1 (100%) are recommending ALLR as a Hold, 0 (0%) are recommending ALLR as a Sell, and 0 (0%) are recommending ALLR as a Strong Sell.
What is ALLR's Earnings Per Share (EPS) forecast for 2023-2023?
(NASDAQ: ALLR) Allarity Therapeutics's current Earnings Per Share (EPS) is -$2.21. In 2023, ALLR's EPS is forecast to hit -$0.91 (min: -$0.91, max: -$0.91).
What is ALLR's forecast return on assets (ROA) for 2023-2023?
(NASDAQ: ALLR) forecast ROA is -187.71%, which is lower than the forecast US Biotechnology industry average of -5.95%.
What is ALLR's earnings growth forecast for 2023-2023?
(NASDAQ: ALLR) Allarity Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of N/A, and while it is not forecast to beat the US market's average forecast earnings growth rate of N/A.
Allarity Therapeutics's earnings in 2023 is -$21,051,000.
In 2023, ALLR is forecast to generate -$27,300,000 in earnings, with the lowest earnings forecast at -$27,300,000 and the highest earnings forecast at -$27,300,000.
What is ALLR's forecast return on equity (ROE) for 2023-2023?
(NASDAQ: ALLR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.